This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

10 Stocks Under $4 With Upside

3. Novavax (NVAX - Get Report) is a clinical-stage biopharmaceutical company developing recombinant vaccines. Using advanced proprietary virus-like particle (VLP) technology, Novavax develops novel vaccines to treat a broad range of infectious diseases worldwide, including H1N1.

The company's future performance is expected positive, based on its funding and licensing deals. In February, the company secured a three-year flu-vaccine contract valued $97 million from the U.S. government. Sources say the contract could be extended for another two years raising the total value by $82.1 million.

Meanwhile, the company announced entering a licensing agreement with LG Life Sciences (LGLS) of South Korea, for using its vaccine technology in South Korea and other countries. The company is expected to receive an undisclosed, upfront and milestone payment from LGLS, in the form of royalty payments from commercial product sales. Also, the HHS Biomedical Advanced Research and Development Authority (BARDA) of the U.S. awarded Novavax a three-year contract worth $97 million with an option to extend it by two additional years, carrying a potential contract value of $179.1 million.

All the four analysts covering the stock recommended a buy rating on it. The stock's average 12-month price target is $6.3, which is 137.6% higher than the stock's current price, as per analysts surveyed by Bloomberg.

8 of 10

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
GLCH $5.94 0.00%
GSI $1.02 0.00%
NVAX $8.07 0.00%
PPHM $1.39 0.00%
WSTL $1.37 0.00%

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs